Conestoga Capital Advisors LLC Grows Stock Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

Conestoga Capital Advisors LLC grew its position in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 15.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,226,262 shares of the technology company’s stock after purchasing an additional 290,414 shares during the quarter. Conestoga Capital Advisors LLC owned approximately 0.11% of Simulations Plus worth $62,090,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SLP. The Manufacturers Life Insurance Company boosted its holdings in Simulations Plus by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after acquiring an additional 456 shares during the period. Azzad Asset Management Inc. ADV raised its holdings in Simulations Plus by 68.7% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 13,505 shares of the technology company’s stock valued at $432,000 after buying an additional 5,498 shares during the last quarter. InTrack Investment Management Inc boosted its position in Simulations Plus by 5.9% during the 3rd quarter. InTrack Investment Management Inc now owns 33,543 shares of the technology company’s stock valued at $1,074,000 after buying an additional 1,878 shares during the period. Kings Path Partners LLC grew its holdings in Simulations Plus by 19.2% in the 3rd quarter. Kings Path Partners LLC now owns 22,560 shares of the technology company’s stock worth $722,000 after acquiring an additional 3,633 shares during the last quarter. Finally, nVerses Capital LLC boosted its holdings in shares of Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after purchasing an additional 1,100 shares during the period. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Price Performance

Shares of Simulations Plus stock opened at $34.32 on Monday. The stock has a market cap of $689.49 million, a price-to-earnings ratio of 85.80 and a beta of 0.82. Simulations Plus, Inc. has a 1 year low of $24.00 and a 1 year high of $51.22. The firm’s 50-day moving average is $30.46 and its 200 day moving average is $32.50.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $31.76, for a total transaction of $635,200.00. Following the sale, the director now owns 3,442,584 shares of the company’s stock, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 19.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on SLP. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Stephens initiated coverage on Simulations Plus in a research report on Friday, November 15th. They set an “overweight” rating and a $39.00 price target on the stock. BTIG Research reduced their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, KeyCorp lifted their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.